It has been reported that, in patients with acute myocardial infarction or congestive heart failure, monocyte chemoattractant protein-1 (MCP-1) plays an important role in the development of inflammatory responses and that the level of MCP-1 is correlated with the severity of the disease. We conducted this study to investigate the effects of dobutamine and dopamine on lipopolysaccharide (LPS)-induced MCP-1 production in human monocytic THP-1 cells. Monocytes were incubated in vitro with LPS for 16 h at 37°C in the presence or absence of dobutamine or dopamine. Enzyme-linked immunosorbent assay was used to examine the effect of dobutamine on MCP-1 synthesis, with the MCP-1 messenger RNA expression examined by reverse transcriptase-polymerase chain reaction. Dobutamine inhibited LPS-induced production of MCP-1, as well as messenger RNA expression, in a dose-dependent manner, whereas dopamine had no significant effect. Furthermore, we demonstrated that dobutamine suppressed MCP-1-induced chemotaxis and peak [Ca 2ϩ ] i in monocytic THP-1 cells. These findings suggest that dobutamine may modulate monocyte activation, such as chemotaxis and [Ca 2ϩ ] i , as well as MCP-1 production, during therapy for congestive heart failure.
T he attraction of leukocytes to tissues is essential for infection, inflammation, and immune response. This process is controlled by chemokines, which are important in the control of leukocyte activation and traffic in several immune-mediated and inflammatory disorders, such as bronchial asthma, rheumatoid arthritis, inflammatory bowel disease, and acute respiratory distress syndrome (1) (2) (3) (4) (5) . There are four families of chemokines according to their sequence homology and the position of the first two cysteine residues, of which there are two main subfamilies: CXC chemokines and CC chemokines (6) . In general, CXC chemokines act predominantly on neutrophils, whereas CC chemokines stimulate monocytes, eosinophils, basophils, and lymphocytes.
Monocyte chemoattractant protein-1 (MCP-1) is a member of the CC chemokine family. It is characterized by chemoattractant activity for monocytes, T cells, mast cells, and basophils (6, 7) . In addition to promoting the transmigration of circulating monocytes into the tissues, MCP-1 exerts various other effects on monocytes, including superoxide anion induction, chemotaxis, and calcium flux (7) . Growing evidence suggests that MCP-1 is important in the immunological and inflammatory processes associated with the pathogenesis and progression of cardiovascular diseases, such as atherosclerosis (8 -10) , acute coronary syndrome (11) , and congestive heart failure (CHF) (12) . An increase of the circulating levels of MCP-1 has been observed in cases of acute myocardial infarction or CHF (13, 14) . Moreover, increased expression of MCP-1 has been demonstrated in the failing myocardium during myocarditis (15) .
The sympathomimetic amines, especially dobutamine and dopamine, have been widely used in the treatment of patients with symptomatic CHF caused by systolic dysfunction. Dobutamine acts mainly as a selective ␤ 1 agonist, exerting a potent inotropic effect with concurrent afterload reduction. Dopamine activates the DA 1 receptors, which increases cerebral, coronary, and renal blood flow and, in combination with its positive inotropic effect, provides hemodynamic benefits (16) . A reputation for CHF treatment has been established for these two drugs over decades of clinical use.
Increased MCP-1 is observed in patients with CHF, and it is critically implicated in the pathogenesis and progression of the disease. Dobutamine and dopamine are the therapeutic mainstay for CHF treatment. This study examines the effects of dobutamine and dopamine on MCP-1 production, because there have been no studies investigating such relationships. In addition, the hypothesis that dobutamine exerts its effect on MCP-1-induced activation of THP-1 monocytic cells, as reflected in chemotaxis and peak intracellular calcium concentration ([Ca 2ϩ ] i ), was also tested.
Methods
The human monocytic cell line THP-1 (American Type Culture Collection, Rockville, MD) was cultured in RPMI 1640 medium (Sigma Chemical Co., St. Louis, MO) supplemented with 10% fetal bovine serum, 100 U/mL of penicillin, and 100 g/mL of streptomycin at 37°C and 5% CO 2 in a humidified incubator. Cells were centrifuged and resuspended in fresh media in 24-well plates at a concentration of 10 6 /mL for 24 h before experimental use.
After 16-h treatments with lipopolysaccharide (LPS) (serotype O111:B4; Sigma Chemical Co.) and/or 0.1-100 M of drugs (dobutamine, dopamine, and salbutamol; Sigma Chemical Co.), supernatants were stored at Ϫ70°C until assay. Determination of MCP-1 concentration was performed according to the manufacturer's recommendations (R & D Systems, Minneapolis, MN) with some modification. Each well of a highbinding-efficiency 96-well enzyme-linked immunosorbent assay plate was coated with mouse antihuman MCP-1 monoclonal antibody (100 L at 1 g/ mL) in phosphate-buffered saline (PBS) at room temperature overnight. The plate was then washed three times with PBS containing 0.05% Tween 20 (PBS-T). Residual binding sites were blocked with 1% bovine serum albumin and 5% sucrose (300 L per well; Sigma Chemical Co.) in PBS with 0.05% NaN 3 and incubated for 1 h at room temperature. After washing with PBS, standard MCP-1 solution or cell supernatants (100 L per well) were added in duplicate to the coated wells, incubated for 2 h at room temperature, and washed 3 times with PBS-T. The plates were then incubated with biotinylated goat anti-human MCP-1 detection antibodies (100 L at 0.1 g/mL) for 2 h at room temperature. After the wash, 100 L of streptavidin horseradish peroxidase (1:2500 dilution of 1.25 mg/mL solution) was added and incubated for 20 min at room temperature. After a triple wash, 100 L of substrate solution containing a 1:1 mixture of H 2 O 2 and tetramethylbenzidine was added and incubated for another 20 min at room temperature. The reaction was stopped by adding 50 L of stop solution (1 M H 2 SO 4 ), and the MCP-1 concentrations were measured with a microplate reader (Dynatech, Guernsey, UK).
The THP-1 cells were incubated at 37°C for 4 h with 0.1 g/mL of LPS in the presence or absence of dobutamine, dopamine, and salbutamol. Total RNA was extracted from cell pellets (1 ϫ 10 6 cells) by using the single-step phenol and guanidine isothiocyanate method (TRIzol; Gibco BRL, Grand Island, NY). The RNA was washed twice in ethanol and precipitated, and the amount of total RNA was quantified by spectrophotometry at 260 nm (Uvikon 940 spectrophotometer; Kontron, Zurich, Switzerland). Total RNA (5 ng per sample) was reverse-transcribed by using SuperScript II RNase H reverse transcriptase (Gibco BRL) and primed with oligo dT according to the manufacturer's instructions. The reaction mixture was incubated at 42°C for 50 min for the reverse-transcription reaction.
In brief, polymerase chain reaction (PCR) was performed with 25 pmol of each primer in a total volume of 25 L. The reaction buffer consisted of 50 mmol/L of Tris-HCl, 0.02 mol/L of (NH 4 ) 2 SO 4 , 1.5 mmol/L of MgCl 2 , 0.2 mmol/L of deoxy nucleoside triphosphate, and 0.05 U/L of DNA polymerase. A minimum of 3 different complementary DNA concentrations served as the template for amplification through 19 -31 cycles of denaturation (60 s at 94°C), primer annealing (60 s at 58°C), and DNA extension (90 s at 72°C) in a GeneAmp PCR System 2400 (PerkinElmer, Norwalk, CT). All amplifications were performed by using a single set of gene-specific sense and antisense oligonucleotide primers designed to flank at least one intron. Amplification of messenger RNA (mRNA) from the housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), was used to produce an internal quality standard. The primer sequences were as follows: MCP-1 sense, 5'-GCTCATAGCAGCCACCTTCATTC 3'; MCP-1 antisense, 5'-TGCAGATTCTTGGGTTGTGGAG 3'; GAPDH sense, 5'-GGGGAGCCAAAAGGGTCATCATCT 3'; and GAPDH antisense, 5'-GAGGGGCCATCCACAGTCTT-CT 3'.
Amplified products were electrophoresed on 1.5% agarose gel stained with ethidium bromide, and a 100-base pair DNA ladder (Gibco BRL) was used as a molecular-weight marker. The sample products were visualized with ultraviolet transillumination, and the gel was photographed. Total RNA from the LPS (0.1 g/mL)-activated monocytic THP-1 cell line (American Type Culture Collection) was used as a positive control. The experimental condition and number of PCR cycles were predetermined to ensure that the amount of MCP-1 and housekeeping gene (GAPDH) fragments were in the linear range of amplification. GAPDH was used as the standard to control for variations in RNA isolation.
Monocyte chemotaxis was measured by using a 24-well Micro Chemotaxis Transwell ® plate (Coring Costar, Cambridge, MA). THP-1 cells were resuspended at 1.5 ϫ 10 6 /mL and transferred to the upper chamber of the Micro Chemotaxis chamber. The chemoattractant, MCP-1 (10 nM in RPMI medium with 1 mg/mL of bovine serum albumin), was added to the lower chamber. The lower and upper chambers were separated by a polycarbonate membrane (5-m pore size). The THP-1 cells were left to transmigrate for 120 min. After a 2-h incubation at 37°C in a humidified atmosphere with 5% CO 2 , the number of monocytes that had migrated to the lower compartment was determined by counting the cells by using light microscopy. Calcium flux assays were performed per the method described previously (17, 18) . For calcium measurements, recombinant human MCP-1 was obtained by using the R & D Systems. Monocytic THP-1 cells were suspended at a density of 2 ϫ 10 6 /mL in Hanks' balanced salt solution containing 1.3 mM CaCl 2 , 10 mM HEPES (pH 7.3), and 1% fetal calf serum (FCS). The cells were loaded with 10 mM Fura-2 AM (Molecular Probes Inc., Eugene, OR) for 1 h at 30°C with occasional shaking. Loaded cells were washed twice with centrifugation and resuspended at a concentration of 10 6 /mL. The temperature of the cell suspension was kept at 37°C, and immediately before each assay, the cells were collected by centrifugation, resuspended in 2 mL of Hanks' balanced salt solution/HEPES/FCS, and added to a cuvette in a temperature-controlled holder (37°C), with continuous stirring. The [Ca 2ϩ ] i was measured by testing the relative ratio of the fluorescence emission intensities ( ex 505 nm) excited both em 340 and 380 nm, by using the AR-CM-MIC Cation Measurement System (Spex Industries Inc.).
All data are presented as mean Ϯ sem. One-way analysis of variance was used for all statistical comparisons, and the Student-Newman-Keuls test was conducted for multiple comparisons. A P value of Ͻ0.05 was considered indicative of significant between-group differences. SigmaStat software (Jandel Scientific, Erkrath, Germany) was used for all statistical analysis.
Results
THP-1 cells were incubated with dobutamine or dopamine to determine whether LPS-induced secretion of MCP-1 was inhibited. After a 16-h incubation, a minimal quantity of MCP-1 was produced by the THP-1 cells in the media (21 Ϯ 1 pg/mL). LPSinduced MCP-1 production (1334 Ϯ 422 pg/mL) was significantly inhibited by dobutamine in a dosedependent manner (Fig. 1 ). Salbutamol's suppressive effect on MCP-1 production was similar to that of dobutamine (Fig. 1) . By contrast, no significant effect on LPS-induced MCP-1 production was demonstrated for dopamine at any of the tested concentrations (Fig.   1 ). To test for dobutamine inhibition of MCP-1 at the transcription level, MCP-1 mRNA content was measured in THP-1 cells incubated with LPS in the presence or absence of dobutamine, dopamine, or salbutamol. Exposure to either dobutamine or salbutamol caused a dose-dependent decrease in MCP-1 mRNA levels, as determined at 4 h after LPS (Fig. 2) . Dopamine had no effect on MCP-1 mRNA levels.
Cell migration was 1.3 Ϯ 0.5 ϫ 10 6 cells in the absence of MCP-1 (random migration), increasing to 2.9 Ϯ 0.6 ϫ 10 6 cells after MCP-1 stimulation. The effect of dobutamine on MCP-1-induced monocyte chemotaxis was assessed in therapeutic (0.1-10 M) and pharmacological (10 -100 M) concentration ranges. As depicted in Figure 3 , treatment of human monocytic THP-1 cells with different concentrations of dobutamine significantly reduced the THP-1 cell chemotaxis induced by MCP-1 (10 nM). By contrast, under the same experimental conditions, dopamine did not inhibit this chemotaxis at any concentration tested. Reduction of dobutamine THP-1 cell chemotaxis was concentration dependent, with 90% of maximal inhibition demonstrated at 100 M in this study.
The increase in [Ca 2ϩ ] i represents a key event in chemokine-induced monocyte activation. A rapid, transient, and concentration-dependent increase in [Ca 2ϩ ] i was observed with MCP-1 treatment (10 nM). Treatment with dobutamine (10 -100 M) reduced MCP-1-induced peak [Ca 2ϩ ] i in THP-1 cells (Fig. 4) .
Discussion
Increasing evidence suggests that MCP-1 is important in the immunological and inflammatory processes associated with the pathogenesis and progression of cardiovascular diseases, such as atherosclerosis, unstable angina, and CHF (14, 15, 19) . This study is the first to clearly demonstrate that, in vitro, dobutamine causes a dose-dependent inhibition of MCP-1 production in human monocytic THP-1 cells. Moreover, we found that dobutamine inhibited LPS-induced MCP-1 mRNA expression, suggesting that dobutamine inhibits MCP-1 production at a transcriptional level. Dopamine has no effect on either MCP-1 protein production or mRNA expression, however. Dobutamine is a ␤ 1 -adrenergic receptor agonist. To determine whether ␤ 2 -specific receptor stimulation can also inhibit MCP-1 production, the effect of salbutamol (a ␤ 2 -adrenergic receptor agonist) was compared with that of dobutamine. The suppressive effect on MCP-1 production was similar for the two. The results suggest that activation of either the ␤ 1 or ␤ 2 receptor may independently inhibit the MCP-1 production response to LPS in monocytes. ␤-Adrenoreceptor activation increases intracellular 3',5'-cyclic adenosine monophosphate (cAMP) through the activation of adenylate cyclase (20, 21) , and increased cAMP levels reduced monocyte cytokine production in other studies (22) (23) (24) . In our study, similar inhibitory effects on MCP-1 production were demonstrated for both dobutamine (␤ 1 ) and salbutamol (␤ 2 ) (81% Ϯ 3% and 50% Ϯ 22% inhibition at 1 M, respectively). This may mainly be a consequence of the increased cAMP levels associated with ␤-adrenoreceptor stimulation in the human monocytic THP-1 cells. Although analysis of our data does not prove that MCP-1 production is positively regulated by cAMP, the results do suggest, at least in part, that these may be such a mechanism.
Activation of leukocytes and migration from the circulation to areas of myocardial inflammation appear to be important factors in the immunological responses associated with CHF (25) . Further, excessive chemokine activation may result in inappropriate inflammation and lead to cell and tissue damage. Additionally, chronic inflammation with leukocyte infiltration has been observed in the failing human myocardium (26) . MCP-1 exhibits chemotactic activity for monocytes and lymphocytes, and it has been postulated that this is a crucial event for the accumulation of mononuclear leukocytes in myocarditis (27) . In patients with acute myocarditis, large plasma MCP-1 levels are correlated with fatal outcome (27) . The MCP-1 that induced chemotaxis was also a potent stimulus for intracellular Ca 2ϩ mobilization in human monocytes. [Ca 2ϩ ] i increase represents a key event in chemokine-induced monocyte activation. By playing a crucial role in the recruitment and activation of leukocytes, MCP-1 may indirectly lead to damage and dysfunction of the cardiac muscle in CHF patients through activation and production of reactive oxygen species (7, 14, 28) . Previously, Tool et al. (29) demonstrated that ␤ 2 -adrenergic agonists and phosphodiesterase inhibitors suppressed the chemotactic response in human eosinophils. In this study, we found that dobutamine suppressed MCP-1-induced chemotaxis and peak [Ca 2ϩ ] i in monocytic THP-1 cells, indicating that dobutamine may suppress the recruitment and activation of leukocytes. However, further evaluation is needed of dobutamine's effects on other biological processes of pathogenic importance in heart failure, including fibrosis, angiogenesis, and apoptosis.
Recent evidence of a possible pathogenic role for chemokines in CHF suggests that modulation of the chemokine network may offer novel therapeutic modalities in these disorders. Moreover, Aukrust et al. (14) demonstrated that monocytes isolated from heart disease patients released larger amounts of MCP-1 in comparison to analogs from healthy subjects; this increase possibly contributed to the pathologic conditions. In this study, dobutamine inhibited MCP-1 production, as well as MCP-1-induced chemotaxis and activation in human monocytic cells. These results suggest that dobutamine may be of benefit in the treatment of congestive heart disease. Further in vivo studies are warranted to establish the impact of dobutamine's effects on MCP-1-mediated monocyte response during inflammation.
In conclusion, we have demonstrated that dobutamine, but not dopamine, inhibits MCP-1 production in human monocytes in vitro and that this regulation occurs, at least in part, at the transcriptional level. Moreover, dobutamine suppresses MCP-1-induced chemotaxis and peak [Ca 2ϩ ] i in human monocytic cells. Therefore, further understanding of the mechanism(s) by which dobutamine inhibits MCP-1 production, as well as MCP-1-induced activation, may help identify and provide insight into therapies that will limit the progression of congestive heart disease.
